Seer Inc (SEER) USD0.00001 A

Sell:$1.97Buy:$1.98No change

NASDAQ:1.26%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.97
Buy:$1.98
Change:No change
Market closed | Prices delayed by at least 15 minutes
Sell:$1.97
Buy:$1.98
Change:No change
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.

Key people

Omid C. Farokhzad
Chairman of the Board, Chief Executive Officer, Co-Founder
David R. Horn
President, Chief Financial Officer, Treasurer
Nicolas Henry Roelofs
Lead Independent Director
Robert S. Langer
Director
Meeta Gulyani
Independent Director
David L. Hallal
Independent Director
Terrance G. Mcguire
Independent Director
Click to see more

Key facts

  • EPIC
    SEER
  • Location
    United States
  • Sector
    Technology
  • Industry
    Scientific & Technical Instr.
  • ISIN
    US81578P1066
  • Market cap
    $121.96m
  • Employees
    134
  • Shares in issue
    55.74m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.